MEDBOT-B (02252) announced that, based on preliminary internal statistics, the cumulative orders for its core products in laparoscopy, orthopedics, and vascular intervention have exceeded 230 units. Among them, the flagship product Toumai laparoscopic surgical robot (Toumai) has secured over 160 commercial orders globally, including nearly 120 new orders this year. According to public statistics, Toumai ranks among the top two globally in terms of 2025 order volume.
Regarding commercial installations, as of the announcement date, the group has completed over 150 commercial installations across its product lines. Notably, Toumai has surpassed 100 global commercial installations, all of which have received signed acceptance reports from users. These transactions comply with the company’s revenue recognition policy, which adheres to Hong Kong accounting standards and industry practices.
Toumai has become the first domestically developed laparoscopic surgical robot to achieve 100 commercial installations, demonstrating industry-leading system reliability, clinical stability, and comprehensive advancements in quality compliance, production processes, engineering validation, system delivery, clinical adaptability, and full-process support capabilities.
In the domestic market, Toumai has made breakthrough progress in top-tier public hospitals and premium private hospitals, with installations covering 23% of the top 100 hospitals and over 90% of tertiary hospitals. This reflects a high-quality installation model driven by clinical value and professional expertise.
Leveraging the group’s proprietary remote technology, hospitals at various levels have established collaborative models such as remote training, technical support, and cross-center joint surgeries. This transforms robotic surgery into a scalable, standardized, and sustainable advanced medical practice, extending high-level surgical capabilities from leading hospitals to regional and grassroots medical centers.
Toumai’s global market share continues to rise, building a replicable, expandable, and sustainably accelerating growth curve. Supported by the group’s deep global multi-tier healthcare network and leading remote technology, a comprehensive robotic surgery ecosystem—connecting top experts, regional medical centers, and grassroots hospitals—is rapidly taking shape.
To date, Toumai’s overseas footprint spans over 40 countries and regions across Asia, Europe, Africa, Oceania, and South America, earning recognition from top-tier institutions. It has achieved multi-unit sales and installations in 15 countries, enabling normalized, networked, and large-scale adoption within diverse global healthcare systems.
Comments